Read this company snapshot
Daily valuation snapshot
Harmony Biosciences Holdings, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $40.28
- Market capitalization (USD)
- $2,345,761,910.04
- Price / earnings (TTM)
- 12.94
- Price / book
- 2.35
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research HRMY in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research HRMY in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing HRMY with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $40.28 |
| Market capitalization (USD) | $2,345,761,910.04 |
| Price / earnings (TTM) | 12.94 |
| Price / book | 2.35 |
No matching rows. Clear the filter to see all records.
Read HRMY's valuation metrics
Company size
Harmony Biosciences Holdings, Inc. Common Stock's recorded market capitalization is $2,345,761,910.04. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
HRMY's recorded P/E is 12.94: about $12.94 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
HRMY's recorded price-to-book ratio is 2.35. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Harmony Biosciences Holdings, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about HRMY. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow HRMY's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.